FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2150147928> ?p ?o ?g. }

• W2150147928 endingPage "496" @default.
• W2150147928 startingPage "496" @default.
• W2150147928 abstract "Juvenile recurrent respiratory papillomatosis (RRP) can be an aggressive disease process necessitating frequent trips to the operating room with multiple anesthetics for tumor debulking and airway preservation. Adjuvant therapy, such as that which is reported in this article, may help reduce the number of operative procedures affected children need each year and therefore may also affect their overall quality of life (QOL).To describe our experience with intralesional bevacizumab (Avastin) treatment for children with severe RRP by comparing median number of surgical procedures per year, median duration of time between procedures, Derkay staging, and voice QOL before and after bevacizumab treatment.Prospective, consecutive case series.Tertiary care aerodigestive center.Ten children, aged 18 months to 18 years, with severe RRP necessitating more than 4 operative interventions in 1 year whose parents (or legal guardians) consented to intralesional bevacizumab treatment.Intralesional bevacizumab administered at concentration of 2.5 mg/mL for 3 consecutive injections (with 532-nm pulsed KTP [potassium titanyl phosphate] laser when necessary) at intervals of 2 to 3 weeks.Time between surgical procedures, number of procedures per year, Derkay staging, total Pediatric Voice-Related Quality of Life (PVRQOL) score, Emotional PVRQOL score, and Physical PVRQOL score defined by comparing the year leading up to first of 3 bevacizumab injections with the year following the third bevacizumab injection.The median duration of time between surgical procedures increased by 5.9 weeks after bevacizumab (P = .002). The median number of procedures per year decreased by 4 (P = .002). Derkay staging decreased by 6 (P = .03). The median total PVRQOL score increased by 25.5 (P = .02), the median Emotional PVRQOL score increased by 11.3 (P = .047), and the median Physical PVRQOL score increased by 14.3 (P = .047).Intralesional bevacizumab treatment may increase duration of time between surgical procedures and decrease number of procedures per year, while improving voice QOL." @default.
• W2150147928 created "2016-06-24" @default.
• W2150147928 creator A5016835626 @default.
• W2150147928 creator A5040198509 @default.
• W2150147928 creator A5048475227 @default.
• W2150147928 creator A5053003046 @default.
• W2150147928 date "2013-05-01" @default.
• W2150147928 modified "2023-10-17" @default.
• W2150147928 title "Use of Adjuvant Intralesional Bevacizumab for Aggressive Respiratory Papillomatosis in Children" @default.
• W2150147928 cites W1968175271 @default.
• W2150147928 cites W1976903522 @default.
• W2150147928 cites W1977574486 @default.
• W2150147928 cites W1983797430 @default.
• W2150147928 cites W1985444027 @default.
• W2150147928 cites W1990736061 @default.
• W2150147928 cites W1993271840 @default.
• W2150147928 cites W1997746557 @default.
• W2150147928 cites W2005291098 @default.
• W2150147928 cites W2007351636 @default.
• W2150147928 cites W2011108910 @default.
• W2150147928 cites W2016006753 @default.
• W2150147928 cites W2020667364 @default.
• W2150147928 cites W2022857499 @default.
• W2150147928 cites W2063591661 @default.
• W2150147928 cites W2084783355 @default.
• W2150147928 cites W2095911820 @default.
• W2150147928 cites W2103128963 @default.
• W2150147928 cites W2106216424 @default.
• W2150147928 cites W2122595579 @default.
• W2150147928 cites W2130263229 @default.
• W2150147928 cites W2137601145 @default.
• W2150147928 cites W2141664895 @default.
• W2150147928 cites W2142693543 @default.
• W2150147928 cites W2147914006 @default.
• W2150147928 cites W2150766933 @default.
• W2150147928 cites W2152423545 @default.
• W2150147928 cites W2161445968 @default.
• W2150147928 cites W2165765234 @default.
• W2150147928 cites W2324677651 @default.
• W2150147928 cites W2326061924 @default.
• W2150147928 cites W2401604009 @default.
• W2150147928 cites W2417059816 @default.
• W2150147928 cites W2522006468 @default.
• W2150147928 cites W2524274040 @default.
• W2150147928 cites W3215022571 @default.
• W2150147928 doi "https://doi.org/10.1001/jamaoto.2013.1810" @default.
• W2150147928 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/23681032" @default.
• W2150147928 hasPublicationYear "2013" @default.
• W2150147928 type Work @default.
• W2150147928 sameAs 2150147928 @default.
• W2150147928 citedByCount "51" @default.
• W2150147928 countsByYear W21501479282013 @default.
• W2150147928 countsByYear W21501479282014 @default.
• W2150147928 countsByYear W21501479282015 @default.
• W2150147928 countsByYear W21501479282016 @default.
• W2150147928 countsByYear W21501479282017 @default.
• W2150147928 countsByYear W21501479282018 @default.
• W2150147928 countsByYear W21501479282019 @default.
• W2150147928 countsByYear W21501479282020 @default.
• W2150147928 countsByYear W21501479282021 @default.
• W2150147928 countsByYear W21501479282022 @default.
• W2150147928 countsByYear W21501479282023 @default.
• W2150147928 crossrefType "journal-article" @default.
• W2150147928 hasAuthorship W2150147928A5016835626 @default.
• W2150147928 hasAuthorship W2150147928A5040198509 @default.
• W2150147928 hasAuthorship W2150147928A5048475227 @default.
• W2150147928 hasAuthorship W2150147928A5053003046 @default.
• W2150147928 hasBestOaLocation W21501479281 @default.
• W2150147928 hasConcept C121608353 @default.
• W2150147928 hasConcept C126322002 @default.
• W2150147928 hasConcept C141071460 @default.
• W2150147928 hasConcept C159110408 @default.
• W2150147928 hasConcept C2776694085 @default.
• W2150147928 hasConcept C2777802072 @default.
• W2150147928 hasConcept C2779951463 @default.
• W2150147928 hasConcept C2780427987 @default.
• W2150147928 hasConcept C2780474809 @default.
• W2150147928 hasConcept C2781100745 @default.
• W2150147928 hasConcept C2910019179 @default.
• W2150147928 hasConcept C71924100 @default.
• W2150147928 hasConceptScore W2150147928C121608353 @default.
• W2150147928 hasConceptScore W2150147928C126322002 @default.
• W2150147928 hasConceptScore W2150147928C141071460 @default.
• W2150147928 hasConceptScore W2150147928C159110408 @default.
• W2150147928 hasConceptScore W2150147928C2776694085 @default.
• W2150147928 hasConceptScore W2150147928C2777802072 @default.
• W2150147928 hasConceptScore W2150147928C2779951463 @default.
• W2150147928 hasConceptScore W2150147928C2780427987 @default.
• W2150147928 hasConceptScore W2150147928C2780474809 @default.
• W2150147928 hasConceptScore W2150147928C2781100745 @default.
• W2150147928 hasConceptScore W2150147928C2910019179 @default.
• W2150147928 hasConceptScore W2150147928C71924100 @default.
• W2150147928 hasIssue "5" @default.
• W2150147928 hasLocation W21501479281 @default.
• W2150147928 hasLocation W21501479282 @default.
• W2150147928 hasOpenAccess W2150147928 @default.
• W2150147928 hasPrimaryLocation W21501479281 @default.
• W2150147928 hasRelatedWork W2006182541 @default.

• next